Ultragenyx Pharmaceutical Inc. (RARE) Stock Price Down 0.2%
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell 0.2% during mid-day trading on Friday . The company traded as low as $49.97 and last traded at $50.12. 111,587 shares changed hands during trading, a decline of 68% from the average session volume of 343,386 shares. The stock had previously closed at $50.00.
A number of brokerages recently issued reports on RARE. Jefferies Group LLC reissued a “hold” rating and set a $68.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, July 14th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Stifel Nicolaus reissued a “buy” rating and set a $85.00 price target (down from $95.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. Cowen and Company reissued an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, June 29th. Finally, JMP Securities lowered their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $74.00.
The firm’s market capitalization is $2.12 billion. The company’s 50 day moving average price is $60.55 and its 200 day moving average price is $64.85.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the business earned ($1.46) earnings per share. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($7.21) EPS for the current fiscal year.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis acquired 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the transaction, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in RARE. Sei Investments Co. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $125,000. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 22.6% in the 1st quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares in the last quarter. Strs Ohio boosted its position in shares of Ultragenyx Pharmaceutical by 10.7% in the 1st quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares in the last quarter. Finally, Kazazian Asset Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $213,000. Institutional investors and hedge funds own 96.18% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.